{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:16Z","timestamp":1785455536640,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012796","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000}}],"reference-count":217,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012796.pub2","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T15:31:08Z","timestamp":1602775868000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Targeted therapy for metastatic renal cell carcinoma"],"prefix":"10.1002","volume":"2020","author":[{"given":"Fabian","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Urology; Sunderby Sjukhus, Ume\u00e5 University; Lule\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas BL","family":"Lam","sequence":"additional","affiliation":[{"name":"Academic Urology Unit; University of Aberdeen; Aberdeen UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[{"name":"Department of Urology and UCL Division of Surgery and Interventional Science; Royal Free London NHS Foundation Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology; McMaster University; Hamilton Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo SO","family":"Marconi","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation; Centro Hospitalar e Universitario de Coimbra; Coimbra Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f6rje","family":"Ljungberg","sequence":"additional","affiliation":[{"name":"Department of Surgical and Perioperative Sciences; Ume\u00e5 University; Ume\u00e5 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"issue":"suppl 4","key":"10.1002\/14651858.CD012796.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"iv290","DOI":"10.1093\/annonc\/mdu337.28","article-title":"Updated overall survival, multivariate, and Q-TWiST analyses of a randomized, sequential, open-label study (SWITCH) to evaluate the efficacy and safety of sorafenib (So)-sunitinib (Su) versus Su-So in the treatment of metastatic renal cell cancer","volume":"25","author":"Eichelberg","year":"2014","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.eururo.2015.04.017","article-title":"SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer","volume":"68","author":"Eichelberg","year":"2015","journal-title":"European Urology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1200\/jco.2014.32.15_suppl.4567","article-title":"Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)\/sunitinib (SU) versus SU\/SO in the treatment of metastatic renal cell cancer (mRCC)","volume":"32","author":"Goebell","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1200\/jco.2014.32.4_suppl.393","article-title":"SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)\/sunitinib (SU) versus SU\/SO in the treatment of metastatic renal cell cancer (mRCC)","volume":"32","author":"Michel","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0005|cit5","unstructured":"Sequential study to treat renal cell carcinoma clinicaltrials.gov\/ct2\/show\/NCT00732914"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1200\/jco.2008.26.15_suppl.5095","article-title":"Efficacy and safety of first-line bevacizumab (BEV) plus interferon-\u03b12a (IFN) in patients (pts) \u226565 years with metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Bajetta","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1359-6349(09)71454-5","article-title":"Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma(mRCC)","volume":"7","author":"Bellmunt","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1359-6349(09)71459-4","article-title":"What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)\/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? \u2013 Experience from AVOREN","volume":"7","author":"Bracarda","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1359-6349(07)71076-5","article-title":"Bevacizumab\/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN)","volume":"5","author":"Bracarda","year":"2007","journal-title":"European Journal of Cancer Supplements"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/jco.2007.25.18_suppl.3","article-title":"A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-a2a vs placebo\/interferon-\u03b12a as first-line therapy in metastatic renal cell carcinoma","volume":"25","author":"Escudier","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"9605","key":"10.1002\/14651858.CD012796.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomized double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"issue":"13","key":"10.1002\/14651858.CD012796.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1200\/jco.2009.27.15_suppl.5020","article-title":"Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-\u03b12a (IFN) in metastatic renal cell carcinoma (mRCC)","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Escudier BJ Negrier S Chevreau C Analysis of prognostic risk categories in the phase III AVOREN trial of first-line bevacizumab plus interferon-\u03b12a in patients with metastatic renal cell carcinoma: French prognostic scoring system Genitourinary Cancers Symposium, ASCO, abst 417 2010","DOI":"10.1200\/jco.2009.27.15_suppl.5020"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1200\/jco.2008.26.15_suppl.5025","article-title":"Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis","volume":"26","author":"Escudier","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1200\/jco.2010.28.15_suppl.4592","article-title":"Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone","volume":"28","author":"Karakiewicz","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Karakiewicz PI Sun M Sneller V Use of a nomogram to quantify progression-free survival benefit in metastatic renal cell carcinoma patients receiving bevacizumab plus interferon or interferon alone Genitourinary Cancers Symposium, ASCO, abstr 392 2010","DOI":"10.1200\/jco.2010.28.15_suppl.4592"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1359-6349(07)71149-7","article-title":"First-line bevacizumab improves progression-free survival with lower doses of interferon-\u03b12a in the treatment of patients with metastatic renal cell carcinoma (AVOREN)","volume":"5","author":"Melichar","year":"2007","journal-title":"European Journal of Cancer Supplements"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/annonc\/mdn161","article-title":"First-line bevacizumab combined with reduced dose interferon-\u03b12a is active in patients with metastatic renal cell carcinoma","volume":"19","author":"Melichar","year":"2008","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0020|cit20","unstructured":"A study of avastin (bevacizumab) added to interferon alfa-2a (roferon) therapy in patients with metastatic renal cell cancer with nephrectomy clinicaltrials.gov\/ct2\/show\/NCT00738530"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(18)30778-2","article-title":"Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial","volume":"20","author":"Cella","year":"2019","journal-title":"Lancet Oncology"},{"issue":"suppl 5","key":"10.1002\/14651858.CD012796.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdx440.029","article-title":"CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups","volume":"28","author":"Escudier","year":"2017","journal-title":"Annals of Oncology"},{"issue":"19","key":"10.1002\/14651858.CD012796.pub2-BIB0023|cit23","first-page":"30413","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"S1470-2045","author":"Motzer","year":"2019","journal-title":"Lancet Oncology"},{"issue":"14","key":"10.1002\/14651858.CD012796.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0025|cit25","unstructured":"Nivolumab combined with ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 214) clinicaltrials.gov\/ct2\/show\/NCT02231749"},{"issue":"6 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1200\/JCO.2018.36.6_suppl.686","article-title":"Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-na\u00efve advanced renal cell carcinoma (aRCC; CheckMate 214)","volume":"28","author":"Tannir","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"5_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0027|cit27","first-page":"17","article-title":"Nivolumab + ipilimumab (N+I) vs sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (aRCC): results from checkmate 214, including overall survival by subgroups","volume":"24","author":"Vyas","year":"2018","journal-title":"Journal of Oncology Pharmacy Practice"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0028|cit28","unstructured":"Alemao E Rajagopalan S Yang S Quality adjusted survival in randomized, controlled trials: application of inverse probability weighting in renal cell cancer Genitourinary Cancers Symposium, ASCO, abstr 399 2010"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1200\/jco.2010.28.15_suppl.4631","article-title":"Serum lactate dehydrogenase as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma","volume":"28","author":"Armstrong","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1200\/jco.2007.25.18_suppl.5033","article-title":"Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma receiving temsirolimus or interferon-alpha","volume":"25","author":"Dutcher","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0031|cit31","unstructured":"Dutcher JP de Souza P Figlin R Effect of temsirolimus versus interferon- on survival of patients with advanced renal cell carcinoma of different histologies Genitourinary Cancers Symposium, ASCO, abstr 384 2008"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"202\u20139","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon- on outcome of patients with advanced renal cell carcinoma of different histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Medical Oncology"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"LBA4","DOI":"10.1200\/jco.2006.24.18_suppl.lba4","article-title":"A phase 3, randomized, 3-arm study of temsirolimus or interferon alpha or the combination in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma","volume":"24","author":"Hudes","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD012796.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2271\u201381","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0035|cit35","unstructured":"Logan T McDermott D Dutcher J Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features Genitourinary Cancers Symposium, ASCO, abstr 281 2009"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0036|cit36","unstructured":"Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (ARCC) clinicaltrials.gov\/ct2\/show\/results\/NCT00065468"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1359-6349(09)71446-6","article-title":"Radiographic findings of drug-induced pneumonitis and clinical correlation inpatients with advanced renal cell carcinoma treated with temsirolimus","volume":"7","author":"Pablo","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/jco.2007.25.18_suppl.5049","article-title":"Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon- (IFN) or the combination of IFN+TEMSR","volume":"25","author":"Parasuraman","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S1359-6349(09)71467-3","article-title":"Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial","volume":"7","author":"Yang","year":"2009","journal-title":"European Journal of Cancer Supplements"},{"issue":"7","key":"10.1002\/14651858.CD012796.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"577\u201384","DOI":"10.2165\/11535290-000000000-00000","article-title":"Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma","volume":"28","author":"Zbrozek","year":"2010","journal-title":"Pharmacoeconomics"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1200\/JCO.2017.35.15_suppl.4505","article-title":"IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun)","volume":"35","author":"Atkins","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2017.35.6_suppl.431","article-title":"A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)","volume":"35","author":"McDermott","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0044|cit44","unstructured":"A study of atezolizumab (an engineered anti-programmed death-ligand 1 [PD-L1] antibody) as monotherapy or in combination with bevacizumab (avastin\u00ae) compared to sunitinib (Sutent\u00ae) in participants with untreated advanced renal cell carcinoma (IMmotion150) clinicaltrials.gov\/ct2\/show\/NCT01984242"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/bju.15058","article-title":"Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma","volume":"126","author":"Pal","year":"2020","journal-title":"BJU Int"},{"issue":"suppl 5","key":"10.1002\/14651858.CD012796.pub2-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/annonc\/mdx440.033","article-title":"IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC)","volume":"28","author":"McDermott","year":"2017","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012796.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/annonc\/mdp067","article-title":"Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population","volume":"20","author":"Castellano","year":"2009","journal-title":"Annals of Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JOP.0922004","article-title":"Quality of life predicts progression-free survival in patients with renal cell carcinoma treated with sunitinib versus interferon alfa","volume":"5","author":"Cella","year":"2009","journal-title":"Journal of Oncology Practice"},{"issue":"22","key":"10.1002\/14651858.CD012796.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.2007.13.5145","article-title":"Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial","volume":"26","author":"Cella","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1200\/jco.2007.25.18_suppl.6594","article-title":"Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-\u03b1)","volume":"25","author":"Cella","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6605552","article-title":"Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-a in a phase III trial: final results and geographical analysis","volume":"102","author":"Cella","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1200\/jco.2008.26.15_suppl.5024","article-title":"Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC)","volume":"26","author":"Figin","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012796.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/cncr.23776","article-title":"Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma","volume":"113","author":"Motzer","year":"2008","journal-title":"Cancer"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1200\/jco.2007.25.18_suppl.5024","article-title":"Sunitinib versus interferon-alfa (IFN-\u03b1) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors","volume":"25","author":"Motzer","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Motzer RJ Figlin RA Hutson TE Tomczak P Bukowski RM Rixe O Sunitinib versus interferon-alfa as first-line treatment of metastatic renal cell carcinoma: updated results and analysis of prognostic factors www.asco.org\/virtual meeting 2007","DOI":"10.1200\/jco.2007.25.18_suppl.5024"},{"issue":"22","key":"10.1002\/14651858.CD012796.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"LBA3","DOI":"10.1200\/jco.2006.24.18_suppl.lba3","article-title":"Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-\u03b1) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC)","volume":"24","author":"Motzer","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1359-6349(07)71140-0","article-title":"Sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC): updated efficacy and safety results and further analysis of prognostic factors","volume":"5","author":"Motzer","year":"2007","journal-title":"European Journal of Cancer Supplements"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0060|cit60","unstructured":"SU011248 versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma clinicaltrials.gov\/ct2\/show\/NCT00083889"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1200\/jco.2010.28.15_suppl.4594","article-title":"TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-\u03b1)","volume":"28","author":"Patil","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1200\/jco.2010.28.15_suppl.4597","article-title":"Validation of kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa: analysis of the pivotal randomized trial","volume":"28","author":"Wilkerson","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1002\/14651858.CD012796.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJMc1400731","article-title":"Overall survival in renal-cell carcinoma with pazopanib versus sunitinib","volume":"370","author":"Motzer","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0065|cit65","unstructured":"Pazopanib versus sunitinib in the treatment of locally advanced and\/or metastatic renal cell carcinoma (COMPARZ) clinicaltrials.gov\/ct2\/show\/NCT00720941"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1200\/jco.2015.33.15_suppl.4557","article-title":"Tivozanib vs sorafenib targeted therapy for advanced renal cell carcinoma: Final results of a phase III trial (901) and efficacy results of a 2nd line tivozanib extension study (902)","volume":"33","author":"Hutson","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"30","key":"10.1002\/14651858.CD012796.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1200\/JCO.2012.47.4940","article-title":"Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial","volume":"31","author":"Motzer","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0068|cit68","unstructured":"A study to compare tivozanib (AV-951) to sorafenib in subjects with advanced renal cell carcinoma (TIVO-1) clinicaltrials.gov\/ct2\/show\/NCT01030783"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/annonc\/mdx075","article-title":"Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC","volume":"28","author":"Knox","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1200\/jco.2015.33.15_suppl.4554","article-title":"Final overall survival analysis for the RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC (mRCC)","volume":"33","author":"Knox","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD012796.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2013.54.6911","article-title":"Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma","volume":"32","author":"Motzer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0072|cit72","unstructured":"Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD-3) clinicaltrials.gov\/ct2\/show\/NCT00903175"},{"issue":"12","key":"10.1002\/14651858.CD012796.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0074|cit74","unstructured":"A study of avelumab with axitinib versus sunitinib in advanced renal cell cancer (JAVELIN Renal 101) clinicaltrials.gov\/ct2\/show\/NCT02684006"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0075|cit75","unstructured":"Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab for the first-line treatment in adult patients with kidney cancer clinicaltrials.gov\/ct2\/show\/study\/NCT00719264"},{"issue":"7","key":"10.1002\/14651858.CD012796.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","article-title":"RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon \u03b1-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma","volume":"26","author":"Ravaud","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0077|cit77","unstructured":"Phase III sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced \/ metastatic renal cell carcinoma (SWITCH-II) clinicaltrials.gov\/ct2\/show\/study\/NCT01613846"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejca.2018.11.001","article-title":"SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33\/11)","volume":"107","author":"Retz","year":"2019","journal-title":"European Journal of Cancer"},{"issue":"suppl 5","key":"10.1002\/14651858.CD012796.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/annonc\/mdx371","article-title":"Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib sorafenib in the treatment of metastatic renal cell carcinoma(SWITCH-II)","volume":"28","author":"Retz","year":"2017","journal-title":"Annals of Oncology"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1200\/jco.2010.28.15_suppl.4525","article-title":"Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)","volume":"28","author":"Halabi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0081|cit81","unstructured":"Harzstark AL Halabi S Stadler WM Hypertensionis associated with clinical outcome for patients with metastatic renal cell carcinoma treated with interferon and bevacizumab on CALGB 90206 Genitourinary Cancers Symposium, ASCO, abstr 351 2010"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0082|cit82","unstructured":"Interferon alfa-2b with or without bevacizumab in treating patients with advanced renal cell carcinoma (Kidney Cancer) clinicaltrials.gov\/ct2\/show\/study\/NCT00072046"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"LBA5019","DOI":"10.1200\/jco.2009.27.18_suppl.lba5019","article-title":"Bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206","volume":"27","author":"Rini","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"33","key":"10.1002\/14651858.CD012796.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB90206","volume":"26","author":"Rini","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0085|cit85","doi-asserted-by":"crossref","unstructured":"Rini BI Halabi S Rosenberg JE CALGB 90206:a phase III trial of bevacizumab plus interferon-alfa versus interferon-alfa monotherapy in metastatic renal cell carcinoma Genitourinary Cancers Symposium, ASCO, abstr 350 2008","DOI":"10.1200\/JCO.2008.16.9847"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancerand Leukemia Group B 90206: a randomized phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0087|cit87","unstructured":"Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT) linicaltrials.gov\/ct2\/show\/NCT00631371"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0089|cit89","unstructured":"IMA901 in patients receiving sunitinib for advanced\/metastatic renal cell carcinoma clinicaltrials.gov\/ct2\/show\/study\/NCT01265901"},{"issue":"11","key":"10.1002\/14651858.CD012796.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0091|cit91","unstructured":"Study to evaluate the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib versus sunitinib monotherapy in participants with renal cell carcinoma (MK-3475-426\/KEYNOTE-426) clinicaltrials.gov\/ct2\/show\/NCT02853331"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2019.37.7_suppl.543","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study","volume":"37(7 suppl)","author":"Powles","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD012796.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD012796.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-19-2838","article-title":"Patient-reported outcomes from the phase 3 randomized IMmotion151 trial: atezolizumab + bevacizumab vs sunitinib in treatment-naive metastatic renal cell carcinoma","volume":"26","author":"Atkins","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1200\/JCO.2018.36.15_suppl.4511","article-title":"Patient-reported outcomes (PROs) in IMmotion151: atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Escudier","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0097|cit97","unstructured":"A study of atezolizumab in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma (RCC) (IMmotion151) clinicaltrials.gov\/ct2\/show\/NCT02420821"},{"issue":"10189","key":"10.1002\/14651858.CD012796.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejca.2011.05.017","article-title":"Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial","volume":"48","author":"Cella","year":"2012","journal-title":"European Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3816\/CGC.2006.n.011","article-title":"A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma","volume":"4","author":"Hutson","year":"2006","journal-title":"Clinical Genitourinary Cancer"},{"issue":"18 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1200\/jco.2007.25.18_suppl.5031","article-title":"Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)","volume":"25","author":"Hutson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0102|cit102","unstructured":"Safety and efficacy of GW786034 (pazopanib) In metastatic renal cell carcinoma clinicaltrials.gov\/ct2\/show\/study\/NCT00334282"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2012.12.010","article-title":"A randomised, double-blind phase III study of pazopanib in patients with advanced and\/or metastatic renal cell carcinoma: Final overall survival results and safety update","volume":"49","author":"Sternberg","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"15S","key":"10.1002\/14651858.CD012796.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1200\/jco.2009.27.15s.5021","article-title":"A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC)","volume":"27","author":"Sternberg","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eururo.2012.08.027","article-title":"Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)","volume":"63","author":"Bracarda","year":"2013","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2014.07.002","article-title":"Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: A randomized first-line phase II trial","volume":"13","author":"Broom","year":"2015","journal-title":"Clinical Genitourinary Cancer"},{"issue":"29","key":"10.1002\/14651858.CD012796.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"4536\u201341","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD012796.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1814\u201323","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamaoncol.2016.5202","article-title":"Alternating treatment with pazopanib and everolimus vs continuous pazopanib to delay disease progressionin patients with metastatic clear cell renal cell cancer: The ROPETAR randomized clinical trial","volume":"3","author":"Cirkel","year":"2017","journal-title":"JAMA Oncology"},{"issue":"23","key":"10.1002\/14651858.CD012796.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1002\/cncr.30942","article-title":"Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer","volume":"123","author":"Dorff","year":"2017","journal-title":"Cancer"},{"issue":"22 Pt 1","key":"10.1002\/14651858.CD012796.pub2-BIB0115|cit115","first-page":"6689\u201395","article-title":"Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma","volume":"13","author":"Ebbinghaus","year":"2007","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/bjc.2015.313","article-title":"A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results","volume":"113","author":"Eisen","year":"2015","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.juro.2007.07.035","article-title":"Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941","volume":"178","author":"Escudier","year":"2007","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1280\u20139","DOI":"10.1200\/JCO.2008.19.3342","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD012796.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1200\/JCO.2015.60.9727","article-title":"BEST: A randomized phase II study of vascular endothelial growth factor, RAF Kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma--A trial of the ECOG-ACRIN cancer research group (E2804)","volume":"33","author":"Flaherty","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"14 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1200\/jco.2004.22.90140.4516","article-title":"Low dose interferon-\u03b12b + thalidomide in patients with previously untreated renal cell cancer. Improvement in progression-free survival but not quality of life or overall survival. A phase III study of the Eastern Cooperative Oncology Group(E2898)","volume":"22","author":"Gordon","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-016-0434-9","article-title":"A randomized, open-Label phase 2 study of the CXCR4 Inhibitor LY2510924 in combination with sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma (RCC)","volume":"11","author":"Hainsworth","year":"2016","journal-title":"Targeted Oncology"},{"issue":"13","key":"10.1002\/14651858.CD012796.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1158\/1078-0432.CCR-15-0580","article-title":"A randomized phase II\/III study of naptumomab estafenatox \u00fe IFNa versus IFNa in renal cell carcinoma: final analysis with baseline biomarker subgroup and trend analysis","volume":"22","author":"Hawkins","year":"2016","journal-title":"Clinical Cancer Research"},{"issue":"13","key":"10.1002\/14651858.CD012796.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","article-title":"Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma","volume":"32","author":"Hutson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/cncr.24685","article-title":"Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma","volume":"116","author":"Jonasch","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdw676","article-title":"A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma","volume":"28","author":"Jonasch","year":"2017","journal-title":"Annals of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1200\/JCO.2005.03.7309","article-title":"Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma","volume":"24","author":"Lee","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012796.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1093\/annonc\/mdv357","article-title":"Randomized phase II trial of sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type Renal cell carcinoma: RESTORE trial","volume":"26","author":"Lee","year":"2015","journal-title":"Annals of Oncology"},{"issue":"14_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"4742","DOI":"10.1200\/jco.2004.22.90140.4742","article-title":"A randomized phase II study of interferon alpha alone or in combination with thalidomide in metastatic renal cancer","volume":"22","author":"Madhusudan","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"9637","key":"10.1002\/14651858.CD012796.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD012796.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","article-title":"Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma:an open-label, randomised phase 3 trial","volume":"15","author":"Motzer","year":"2014","journal-title":"Lancet Oncology"},{"issue":"19","key":"10.1002\/14651858.CD012796.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1200\/jco.2014.32.15_suppl.5009","article-title":"Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial","volume":"32","author":"Motzer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012796.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejca.2011.12.022","article-title":"Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study","volume":"48","author":"Mulders","year":"2012","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD012796.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","article-title":"Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial","volume":"12","author":"N\u00e9grier","year":"2011","journal-title":"Lancet Oncology"},{"issue":"14","key":"10.1002\/14651858.CD012796.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2011.35.3524","article-title":"Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma","volume":"30","author":"Nosov","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"15","key":"10.1002\/14651858.CD012796.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-14-3370","article-title":"A Phase I\/II trial of BNC105P with everolimus in metastatic renal cell carcinoma","volume":"21","author":"Pal","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1200\/jco.2015.33.15_suppl.4549","article-title":"Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805]","volume":"33","author":"Pili","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1200\/jco.2014.32.15_suppl.4525","article-title":"A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)","volume":"32","author":"Powles","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.eururo.2015.08.035","article-title":"A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer","volume":"69","author":"Powles","year":"2016","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"880\u20136","DOI":"10.1093\/annonc\/mdw014","article-title":"A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer(COSAK)","volume":"27","author":"Powles","year":"2016","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/bjc.2011.103","article-title":"Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial","volume":"104","author":"Procopio","year":"2011","journal-title":"British Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD012796.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD012796.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1200\/JCO.2007.14.5029","article-title":"Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial","volume":"26","author":"Ravaud","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"9807","key":"10.1002\/14651858.CD012796.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"24","key":"10.1002\/14651858.CD012796.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1002\/cncr.27632","article-title":"AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study","volume":"118","author":"Rini","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD012796.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1464-410X.2005.05680.x","article-title":"A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma","volume":"96","author":"Srinivas","year":"2005","journal-title":"BJU International"},{"issue":"16","key":"10.1002\/14651858.CD012796.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1200\/JCO.2005.44.150","article-title":"Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma -CALGB 69901","volume":"23","author":"Stadler","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"European Urology"},{"issue":"6_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1200\/JCO.2018.36.6_suppl.583","article-title":"A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial)","volume":"36","author":"Tannir","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"4_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1200\/jco.2014.32.4_suppl.502","article-title":"Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favourable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC","volume":"32","author":"Tomita","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1200\/jco.2015.33.15_suppl.4523","article-title":"SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC)","volume":"33","author":"Twardowski","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"15_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"TPS4598","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4598","article-title":"A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER)","volume":"36","author":"Choueiri","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0159|cit159","unstructured":"A study of nivolumab combined with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma (CheckMate 9ER) clinicaltrials.gov\/ct2\/show\/NCT03141177"},{"issue":"6_suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"TPS767","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS767","article-title":"A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk","volume":"38","author":"Choueiri","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0161|cit161","unstructured":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (COSMIC-313) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03937219"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0162|cit162","first-page":"75","article-title":"A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor (NIVOSWITCH)","volume":"41","author":"Grunwald","year":"2018","journal-title":"Oncology Research and Treatment"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0163|cit163","unstructured":"Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02959554"},{"issue":"6 suppl","key":"10.1002\/14651858.CD012796.pub2-BIB0164|cit164","doi-asserted-by":"publisher","first-page":"TPS706","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS706","article-title":"A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma","volume":"36","author":"Motzer","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0165|cit165","unstructured":"Lenvatinib\/everolimus or Lenvatinib\/pembrolizumab versus sunitinib alone as treatment of advanced renal cell carcinoma (CLEAR) clinicaltrials.gov\/ct2\/show\/study\/NCT02811861"},{"issue":"23","key":"10.1002\/14651858.CD012796.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1200\/JCO.2005.23.648","article-title":"Intracellular signal transduction pathway proteins as targets for cancer therapy","volume":"23","author":"Adjei","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.2005.03.6913","article-title":"When does the presence of the target predict response to the targeted agent?","volume":"24","author":"Bergsland","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0168|cit168","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001425.pub2","article-title":"Immunotherapy for advanced renal cell cancer","author":"Coppin","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0169|cit169","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0170|cit170","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) on behalf of the Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD012796.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukeamia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0172|cit172","unstructured":"Ljungberg B Albiges L Bensalah K Bex A Giles RH Hora M EAU Guidelines on Renal Cell Carcinoma. Edn. presented at the EAU Annual Congress Amsterdam EAU Guidelines Office"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","article-title":"A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma","volume":"71","author":"Fern\u00e1ndez-Pello","year":"2017","journal-title":"European Urology"},{"issue":"18","key":"10.1002\/14651858.CD012796.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199804303381804","article-title":"Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma","volume":"338","author":"Gleave","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0177|cit177","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0178|cit178","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"7650","key":"10.1002\/14651858.CD012796.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11523-010-0144-7","article-title":"Emerging molecular classification in renal cell carcinoma: implications for drug development","volume":"5","author":"Hacker","year":"2010","journal-title":"Targeted Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"d7202","DOI":"10.1136\/bmj.d7202","article-title":"Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses","volume":"344","author":"Hart","year":"2012","journal-title":"BMJ"},{"issue":"11","key":"10.1002\/14651858.CD012796.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012796.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"Journal of the Royal Statistical Society. Series A, (Statistics in Society)"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0186|cit186","unstructured":"Higgins JPT Churchill R Chandler J Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0187|cit187","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0188|cit188","unstructured":"Howlader N Noone AM Krapcho M Miller D Bishop K Kosary CL SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD seer.cancer.gov\/csr\/1975_2014\/,"},{"issue":"8","key":"10.1002\/14651858.CD012796.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/jnci\/djr062","article-title":"Accelerated approval of oncology products: the Food and Drug Adminstration experience","volume":"103","author":"Johnson","year":"2011","journal-title":"Journal of the National Cancer Institute"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ccr.2008.11.005","article-title":"Kidney cancer: now available in a new flavor","volume":"14","year":"2008","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10456-017-9550-0","article-title":"Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer","volume":"20","author":"Kuusk","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani","year":"2018","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1464-410X.2005.05189.x","article-title":"The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management","volume":"95 Suppl 2","author":"Linehan","year":"2005","journal-title":"BJU International"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0302-2838(03)00105-2","article-title":"Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma","volume":"43","author":"Mickisch","year":"2003","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1464-410X.1989.tb05147.x","article-title":"Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma","volume":"63","author":"Oliver","year":"1989","journal-title":"British Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/cncr.24713","article-title":"Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients","volume":"116","author":"Patil","year":"2010","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0198|cit198","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"d549","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1002\/14651858.CD012796.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2003.01.204","article-title":"The phase III trial in the era of targeted therapy: unravelling the \"go or no go\" decision","volume":"21","author":"Chabner","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"7015","key":"10.1002\/14651858.CD012796.pub2-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/nature03095","article-title":"Targeted cancer therapy","volume":"432","author":"Sawyers","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD012796.pub2-BIB0203|cit203","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000098","article-title":"Regulatory agencies hold the key to improving Cochrane Reviews of drugs","author":"Schroll","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0204|cit204","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD012796.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/PAS.0b013e318299f2d1","article-title":"The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia","volume":"37","author":"Srigley","year":"2013","journal-title":"American Journal of Surgical Pathology"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2005.04.2408","article-title":"New targets, therapies, and toxicities: lessons to be learned","volume":"24","author":"Stadler","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012796.pub2-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD012796.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nature Reviews Cancer"},{"issue":"5","key":"10.1002\/14651858.CD012796.pub2-BIB0209|cit209","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011673.pub2","article-title":"Immunotherapy for metastatic renal cell carcinoma","author":"Unverzagt","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0094-0143(03)00021-1","article-title":"The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician","volume":"30","author":"Uzzo","year":"2003","journal-title":"Urologic Clinics of North America"},{"issue":"3","key":"10.1002\/14651858.CD012796.pub2-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.eururo.2018.03.036","article-title":"First-line systemic therapy for metastatic renal cell carcinoma: A systematic review and network meta-analysis","volume":"74","author":"Wallis","year":"2018","journal-title":"European Urology"},{"issue":"7644","key":"10.1002\/14651858.CD012796.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"issue":"24","key":"10.1002\/14651858.CD012796.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1158\/1078-0432.CCR-09-2131","article-title":"Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma","volume":"15","author":"Young","year":"2009","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.1002\/14651858.CD012796.pub2-BIB0214|cit214","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006017","article-title":"Targeted therapy for advanced renal cell carcinoma","author":"Coppin","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD012796.pub2-BIB0215|cit215","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006017.pub2","article-title":"Targeted therapy for advanced renal cell carcinoma","author":"Coppin","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD012796.pub2-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","article-title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials","volume":"108","author":"Coppin","year":"2011","journal-title":"BJU International"},{"issue":"9","key":"10.1002\/14651858.CD012796.pub2-BIB0217|cit217","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012796","article-title":"Targeted therapy for metastatic renal cell carcinoma","author":"Hofmann","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,2,25]],"date-time":"2024-02-25T11:20:31Z","timestamp":1708860031000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012796.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":217,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012796.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]}}}